- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 695131, 6 pages
Kidney Diseases Caused by Complement Dysregulation: Acquired, Inherited, and Still More to Come
1Division of Internal Medicine, University Hospital Zurich, Raemistrasse 100, 8006 Zurich, Switzerland
2Division of Nephrology, University Hospital Zurich, Raemistrasse 100, 8006 Zurich, Switzerland
Received 6 August 2012; Accepted 11 October 2012
Academic Editor: Michael A. Flierl
Copyright © 2012 Saskia F. Heeringa and Clemens D. Cohen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. J. Walport, “Advances in immunology: complement (first of two parts),” The New England Journal of Medicine, vol. 344, no. 14, pp. 1058–1066, 2001.
- M. J. Walport, “Advances in immunology: complement (second of two parts),” The New England Journal of Medicine, vol. 344, no. 15, pp. 1140–1144, 2001.
- B. Holst, A.-C. Raby, J. E. Hall, and M. O. Labéta, “Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a,” Anaesthesia, vol. 67, no. 1, pp. 60–64, 2012.
- P. F. Zipfel and C. Skerka, “Complement regulators and inhibitory proteins,” Nature Reviews Immunology, vol. 9, no. 10, pp. 729–740, 2009.
- F. Fakhouri, V. Frémeaux-Bacchi, L. H. Noël, H. T. Cook, and M. C. Pickering, “C3 glomerulopathy: a new classification,” Nature Reviews Nephrology, vol. 6, no. 8, pp. 494–499, 2010.
- S. Sethi and F. C. Fervenza, “Membranoproliferative glomerulonephritis—a new look at an old entity,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1119–1131, 2012.
- D. P. Gale, E. G. de Jorge, H. T. Cook et al., “Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis,” The Lancet, vol. 376, no. 9743, pp. 794–801, 2010.
- J. Caprioli, P. Bettinaglio, P. F. Zipfel et al., “The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20,” Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 297–307, 2001.
- E. C. Jackson, A. J. McAdams, C. F. Strife, J. Forristal, T. R. Welch, and C. D. West, “Differences between membranoproliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation,” American Journal of Kidney Diseases, vol. 9, no. 2, pp. 115–120, 1987.
- S. Sethi, C. M. Nester, and R. J. H. Smith, “Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion,” Kidney International, vol. 81, no. 5, pp. 434–441, 2012.
- S. Sethi, F. C. Fervenza, Y. Zhang et al., “Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 5, pp. 1009–1017, 2011.
- A. Servais, L.-H. Noël, L. T. Roumenina et al., “Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies,” Kidney International, vol. 82, no. 4, pp. 454–464, 2012.
- J. L. McRae, T. G. Duthy, K. M. Griggs et al., “Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein,” Journal of Immunology, vol. 174, no. 10, pp. 6250–6256, 2005.
- Y. Athanasiou, K. Voskarides, D. P. Gale et al., “Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1436–1446, 2011.
- L. G. Fritsche, N. Lauer, A. Hartmann et al., “An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD),” Human Molecular Genetics, vol. 19, no. 23, pp. 4694–4704, 2010.
- A. G. Gharavi, K. Kiryluk, M. Choi et al., “Genome-wide association study identifies susceptibility loci for IgA nephropathy,” Nature Genetics, vol. 43, no. 4, pp. 321–327, 2011.
- T. H. Malik, P. J. Lavin, E. G. De Jorge et al., “A hybrid CFHR3-1 gene causes familial C3 glomerulopathy,” Journal of the American Society of Nephrology, vol. 23, no. 7, pp. 1155–1160, 2012.
- S. Sethi, F. C. Fervenza, Y. Zhang et al., “C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up,” Kidney International, vol. 82, no. 4, pp. 465–473, 2012.
- R. J. H. Smith, C. L. Harris, and M. C. Pickering, “Dense deposit disease,” Molecular Immunology, vol. 48, no. 14, pp. 1604–1610, 2011.
- S. Sethi, J. D. Gamez, J. A. Vrana et al., “Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway,” Kidney International, vol. 75, no. 9, pp. 952–960, 2009.
- R. E. Spitzer, E. H. Vallota, J. Forristal et al., “Serum C′3 lytic system in patients with glomerulonephritis,” Science, vol. 164, no. 3878, pp. 436–437, 1969.
- Y. Zhang, N. C. Meyer, K. Wang et al., “Causes of alternative pathway dysregulation in dense deposit disease,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 265–274, 2012.
- A. T. Gewurz, S. M. Imherr, S. Strauss, H. Gewurz, and C. Mold, “C3 nephritic factor and hypocomplementaemia in a clinically healthy individual,” Clinical and Experimental Immunology, vol. 54, no. 1, pp. 253–258, 1983.
- T. H. J. Goodship, I. Y. Pappworth, T. Toth et al., “Factor H autoantibodies in membranoproliferative glomerulonephritis,” Molecular Immunology, vol. 52, no. 3-4, pp. 200–206, 2012.
- C. Licht, U. Schlötzer-Schrehardt, M. Kirschfink, P. F. Zipfel, and B. Hoppe, “MPGN II—genetically determined by defective complement regulation?” Pediatric Nephrology, vol. 22, no. 1, pp. 2–9, 2007.
- Q. Chen, D. Müller, B. Rudolph et al., “Combined C3b and factor B autoantibodies and MPGN type II,” The New England Journal of Medicine, vol. 365, no. 24, pp. 2340–2342, 2011.
- T. S. Jokiranta, A. Solomon, M. K. Pangburn, P. F. Zipfel, and S. Meri, “Nephritogenic λ light chain dimer: a unique human miniautoantibody against complement factor H,” Journal of Immunology, vol. 163, no. 8, pp. 4590–4596, 1999.
- S. Strobel, M. Zimmering, K. Papp, J. Prechl, and M. Józsi, “Anti-factor B autoantibody in dense deposit disease,” Molecular Immunology, vol. 47, no. 7-8, pp. 1476–1483, 2010.
- L. Anne-Laure, M. Malina, V. Fremeaux-Bacchi et al., “Eculizumab in severe shiga-toxin—associated HUS,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2561–2563, 2011.
- J. Menne, M. Nitschke, R. Stingele et al., “Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study,” British Medical Journal, vol. 345, no. 7869, Article ID e4565, 2012.
- E. Daina, M. Noris, and G. Remuzzi, “Eculizumab in a patient with dense-deposit disease,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1161–1163, 2012.
- S. Radhakrishnan, A. Lunn, M. Kirschfink et al., “Eculizumab and refractory membranoproliferative glomerulonephritis,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1165–1166, 2012.
- M. Vivarelli, A. Pasini, and F. Emma, “Eculizumab for the treatment of dense-deposit disease,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1163–1165, 2012.
- A. S. Bomback, R. J. Smith, G. R. Barile et al., “Eculizumab for dense deposit disease and C3 glomerulonephritis,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 748–756, 2012.
- L. C. Herlitz, A. S. Bomback, G. S. Markowitz et al., “Pathology after eculizumab in dense deposit disease and C3 GN,” Journal of the American Society of Nephrology, vol. 23, no. 7, pp. 1229–1237, 2012.
- S. Habbig, M. J. Mihatsch, S. Heinen et al., “C3 deposition glomerulopathy due to a functional factor H defect,” Kidney International, vol. 75, no. 11, pp. 1230–1234, 2009.
- C. Licht, A. Weyersberg, S. Heinen et al., “Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15,” American Journal of Kidney Diseases, vol. 45, no. 2, pp. 415–421, 2005.
- S. Sethi, F. C. Fervenza, Y. Zhang, and R. J. H. Smith, “Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3,” American Journal of Kidney Diseases, vol. 60, no. 2, pp. 316–321, 2012.
- R. C. Wiggins, “The spectrum of podocytopathies: a unifying view of glomerular diseases,” Kidney International, vol. 71, no. 12, pp. 1205–1214, 2007.